AU2018384790C1 - Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa - Google Patents

Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa Download PDF

Info

Publication number
AU2018384790C1
AU2018384790C1 AU2018384790A AU2018384790A AU2018384790C1 AU 2018384790 C1 AU2018384790 C1 AU 2018384790C1 AU 2018384790 A AU2018384790 A AU 2018384790A AU 2018384790 A AU2018384790 A AU 2018384790A AU 2018384790 C1 AU2018384790 C1 AU 2018384790C1
Authority
AU
Australia
Prior art keywords
ala
leu
gly
arg
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018384790A
Other languages
English (en)
Other versions
AU2018384790A1 (en
AU2018384790B2 (en
Inventor
Chiara INDIANI
Raymond Schuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contrafect Corp
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of AU2018384790A1 publication Critical patent/AU2018384790A1/en
Publication of AU2018384790B2 publication Critical patent/AU2018384790B2/en
Application granted granted Critical
Publication of AU2018384790C1 publication Critical patent/AU2018384790C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018384790A 2017-12-12 2018-12-12 Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa Ceased AU2018384790C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762597577P 2017-12-12 2017-12-12
US62/597,577 2017-12-12
US201862721969P 2018-08-23 2018-08-23
US62/721,969 2018-08-23
PCT/US2018/065265 WO2019118632A1 (en) 2017-12-12 2018-12-12 Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa

Publications (3)

Publication Number Publication Date
AU2018384790A1 AU2018384790A1 (en) 2020-07-30
AU2018384790B2 AU2018384790B2 (en) 2024-10-17
AU2018384790C1 true AU2018384790C1 (en) 2025-05-01

Family

ID=66819724

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018384790A Ceased AU2018384790C1 (en) 2017-12-12 2018-12-12 Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa

Country Status (11)

Country Link
US (1) US12121568B2 (cg-RX-API-DMAC7.html)
EP (1) EP3723789A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021506769A (cg-RX-API-DMAC7.html)
KR (1) KR20200098615A (cg-RX-API-DMAC7.html)
CN (1) CN111971058A (cg-RX-API-DMAC7.html)
AU (1) AU2018384790C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020011433A2 (cg-RX-API-DMAC7.html)
CA (1) CA3085644A1 (cg-RX-API-DMAC7.html)
IL (2) IL275060B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020006098A (cg-RX-API-DMAC7.html)
WO (1) WO2019118632A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
US20210062137A1 (en) * 2017-12-22 2021-03-04 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF
MX2021012166A (es) * 2019-04-05 2021-11-03 Contrafect Corp Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
KR102225240B1 (ko) * 2019-07-03 2021-03-10 경북대학교 산학협력단 다제내성 병원성 세균을 효과적으로 사멸시키는 재조합 항균 단백질 Ablysin의 용도
JP2023502940A (ja) * 2019-11-14 2023-01-26 コントラフェクト コーポレイション 溶解素-抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用
US20250324979A1 (en) * 2021-09-03 2025-10-23 Alexandre Ismail LysECD7 VARIANTS AND METHODS OF USING THE SAME
CN114410670B (zh) * 2022-01-29 2024-01-23 福建医科大学附属口腔医院 一种溶菌酶及其在口腔护理用品中的应用
CN117660413B (zh) * 2023-12-15 2024-06-07 华南理工大学 一种内溶素Lys009及其工程改造和应用
CN120173923B (zh) * 2025-05-08 2026-06-30 浙江大学 与PeiR裂解酶高维特征同源的产甲烷菌裂解酶及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049233A2 (en) * 2015-09-17 2017-03-23 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
ES2761835T3 (es) 2009-02-06 2020-05-21 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos
WO2011060920A2 (en) * 2009-11-18 2011-05-26 Basf Plant Science Company Gmbh Process for the production of fine chemicals
DK2563916T3 (en) * 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
MX383544B (es) 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
BR112016030580B1 (pt) 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
CN108103050A (zh) 2018-02-11 2018-06-01 中国医药集团总公司四川抗菌素工业研究所 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3840771A4 (en) 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049233A2 (en) * 2015-09-17 2017-03-23 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria

Also Published As

Publication number Publication date
BR112020011433A2 (pt) 2020-12-01
IL303122A (en) 2023-07-01
IL275060B1 (en) 2023-06-01
MX2020006098A (es) 2020-08-24
AU2018384790A1 (en) 2020-07-30
US20210085758A1 (en) 2021-03-25
RU2020118691A (ru) 2022-01-13
IL275060A (en) 2020-07-30
JP2021506769A (ja) 2021-02-22
IL275060B2 (en) 2023-10-01
AU2018384790B2 (en) 2024-10-17
CN111971058A (zh) 2020-11-20
EP3723789A4 (en) 2021-12-01
EP3723789A1 (en) 2020-10-21
KR20200098615A (ko) 2020-08-20
US12121568B2 (en) 2024-10-22
JP2024010053A (ja) 2024-01-23
WO2019118632A1 (en) 2019-06-20
CA3085644A1 (en) 2019-06-20
JP7646237B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
AU2018384790B2 (en) Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
CN108348574B (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
KR20200045468A (ko) 용균 단백질 항균 활성의 혈액 성분 강화 및 이의 방법 및 용도
KR20210024005A (ko) 스태필로코커스 아우레우스 및 그람 양성 세균을 항생제에 재민감화시키기 위한 리신 및 이의 유도체
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
CN112118861A (zh) 修饰的PlySs2溶素及其用途
Kumar Natural peptides and their synthetic congeners acting against Acinetobacter baumannii through the membrane and cell wall: latest progress
EP3946609A1 (en) Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum
EP3727451B1 (en) Recombinant pseudomonas aeruginosa lysins
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
EP3813796A1 (en) Recombinant lysins
US20220024992A1 (en) Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾PlySs2溶解素及び抗生物質の組合せ

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JAN 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 06 JAN 2025

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired